This draft guidance document for industry and FDA staff describes the Food and Drug Administration's proposed program to evaluate a globally harmonized alternative for premarket procedures. The program is intended to assess the feasibility of an internationally harmonized format and content for premarket submissions, e.g., premarket notification (510(k))submissions and premarket approval (PMA) applications. The following is a link to the complete set of documents.
http://www.fda.gov/cdrh/ode/guidance/1347.htmlFDA's proposed 'globally harmonized' PMA alternative
Jul 24, 2001
Latest in Regulatory
NQF seeks comments on 'high stakes' healthcare quality measurement
September 26, 2025
ACR CEO talks imaging’s role in spending bill
September 23, 2025
HeartFlow secures 510(k) for next-gen algorithm
September 23, 2025
RBMA sends commentary to CMS on MPFS Proposed Rule
September 9, 2025